EGFR and neoplasm: The anti-EGFR TKI AG1478 has shown to increase mAb 806-reactive dimers on the surface of cells overexpressing EGFR, and the combination has of mAb806 and AG1478 resulted in enhanced anti-tumour activity in xenograft models (159).